| 1 |
Argirò A, Zampieri M, Dei LL, Ferrantini C, Marchi A, Tomberli A, Baldini K, Cappelli F, Favilli S, Passantino S, Zocchi C, Tassetti L, Gabriele M, Maurizi N, Marchionni N, Coppini R, Olivotto I. Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: Real-world experience in a National Referral Center. Int J Cardiol 2023;370:271-8. [PMID: 36228766 DOI: 10.1016/j.ijcard.2022.10.014] [Reference Citation Analysis]
|
| 2 |
Pelliccia F, Cecchi F, Olivotto I, Camici PG. Microvascular Dysfunction in Hypertrophic Cardiomyopathy. JCM 2022;11:6560. [DOI: 10.3390/jcm11216560] [Reference Citation Analysis]
|
| 3 |
Minhas AMK, Wyand RA, Ariss RW, Nazir S, Shahzeb Khan M, Jia X, Greene SJ, Fudim M, Wang A, Warraich HJ, Kalra A, Alam M, Virani SS. Demographic and Regional Trends of Hypertrophic Cardiomyopathy-Related Mortality in the United States, 1999 to 2019. Circ Heart Fail 2022;15:e009292. [PMID: 36126142 DOI: 10.1161/CIRCHEARTFAILURE.121.009292] [Reference Citation Analysis]
|
| 4 |
Garcia Brás P, Aguiar Rosa S, Thomas B, Fiarresga A, Cardoso I, Pereira R, Branco G, Cruz I, Baquero L, Cruz Ferreira R, Mota Carmo M, Rocha Lopes L. Associations between perfusion defects, tissue changes and myocardial deformation in hypertrophic cardiomyopathy, uncovered by a cardiac magnetic resonance segmental analysis. Revista Portuguesa de Cardiologia 2022;41:559-568. [DOI: 10.1016/j.repc.2022.03.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 5 |
Toste A. Uncovering hypertrophic cardiomyopathy pathophysiology – the unsolved role of microvascular dysfunction. Revista Portuguesa de Cardiologia 2022. [DOI: 10.1016/j.repc.2022.05.005] [Reference Citation Analysis]
|
| 6 |
Venet M, Friedberg MK, Mertens L, Baranger J, Jalal Z, Tlili G, Villemain O. Nuclear Imaging in Pediatric Cardiology: Principles and Applications. Front Pediatr 2022;10:909994. [PMID: 35874576 DOI: 10.3389/fped.2022.909994] [Reference Citation Analysis]
|
| 7 |
Puwanant S, Trongtorsak A, Wanlapakorn C, Songsirisuk N, Ariyachaipanich A, Boonyaratavej S. Acute coronary syndrome with non-obstructive coronary arteries (ACS-NOCA) in patients with hypertrophic cardiomyopathy. BMC Cardiovasc Disord 2021;21:556. [PMID: 34798824 DOI: 10.1186/s12872-021-02373-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Glavaški M, Velicki L. Shared Molecular Mechanisms of Hypertrophic Cardiomyopathy and Its Clinical Presentations: Automated Molecular Mechanisms Extraction Approach. Life (Basel) 2021;11:785. [PMID: 34440529 DOI: 10.3390/life11080785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
